Q-omics provides the consensus-scored MTHFD2P6 profile across patient tissues and cancer cell-line models. MTHFD2P6 expression is associated with patient survival in 14 of 34 cancer types, with the highest sampling consensus in THYM. Among the 18 cancer types available for tumor–normal comparison, MTHFD2P6 is differentially expressed in 3, with the highest sampling consensus in BRCA. Additionally, MTHFD2P6 RNA expression shows 6,185 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight THYM, BRCA, and STAD as cancer lineages where MTHFD2P6 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MTHFD2P6 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MTHFD2P6 survival associations across molecular data types. MTHFD2P6 RNA expression shows survival associations in the most cancer types (14). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MTHFD2P6 RNA expression–survival associations across cancer types. High MTHFD2P6 expression shows unfavorable associations in THYM, DLBC, MESO and ACC, but favorable associations in UCEC and BRCA. The THYM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify THYM as the clearest survival context for MTHFD2P6 RNA expression.
This table summarizes MTHFD2P6 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for MTHFD2P6. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MTHFD2P6 shows lower tumor expression in THCA and higher tumor expression in BRCA and KIRC. The BRCA box plot shows higher MTHFD2P6 RNA expression in tumor versus normal tissue (log2 FC = +0.033, t-test p = .045).
This table shows molecular features associated with MTHFD2P6 in patient tissues and cancer cell lines. In patient samples, MTHFD2P6 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
